D. Western Therapeutics Institute (4576 JP) - September 25, 2025

292 Views25 Sep 2025 20:08

Issuer-paid

SUMMARY

DWTI announced before the open on 9/25 that the US FDA (Food and Drug Administration) has granted marketing approval for DW-5LBT (lidocaine patch, trade name Bondlido), as a treatment for neuropathic pain after shingles (post- herpetic neuralgia) in adults, jointly developed with MEDRx (4586 TSE Growth).
Earlier this week on Monday 9/22, DWTI announced that the FDA had conditionally approved a change in the trade name from “Lydolyte” to “Bondlido” (the FDA had requested a name change to avoid confusion with an existing product).
Preparations for the launch will be made, including the selection of sales partners, with sales planned to begin in the US in the first half of 2026.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream